Percutaneous closure of ventricular septal defect using LifeTech^TM Konar-MF VSD Occluder: initial and short-term multi-institutional results

Abstract

Background: Transcatheter ventricular septal defect closure remains a complex procedure with potential complications like complete heart block and aortic regurgitation. The ideal device design for such intervention is still evolving. Aim: To assess the safety, efficacy, and short-term outcome of ventricular septal defect closure using LifeTechTM multifunctional (KONAR-MFTM) VSD Occluder. Patients and methods: In a multicenre study, 44 patients with haemodynamically significant, restrictive ventricular septal defects underwent closure with the KONAR-MFTM device from April, 2019 to March, 2020. Clinical, echocardiographic, and angiographic data were collected and reviewed. Patients were followed up at 1, 3, 6, and 12 months. Results: The median age and weight were 8 (1.7–36) years and 20 (11–79) kg. Of 44 patients, 8 (18%) had a high muscular and 36 (82%) had a perimembranous defect, of which 6 had mild prolapse of the right coronary cusp. The median ventricular septal defect size was 8.8 (3.9–13.4) mm. A retrograde approach was adopted in 39 (88.6%) patients. Nine patients (20.5%) had a small residual leak and there was a slight increase in aortic regurgitation in one patient. One device, which embolised to pulmonary artery was retrieved, and the defect was closed with a larger device. At a median follow-up of 13 (5–18) months, the residual leak persisted in 1 (2.3%) patient. Mild aortic regurgitation in one patient remained unchanged. There were no major complications. Conclusion: Percutaneous closure of ventricular septal defect using KONAR-MFTM device is safe and effective in short and midterm follow-up including selected patients with perimembranous defect and mild prolapse of the right coronary cusp.

Early and mid-term outcomes of transcatheter closure of perimembranous ventricular septal defects using the Lifetech™ Konar-MF Occluder device (MFO)

“…Because the radial stress force of the MFO is much lower than that of other double-disc devices, its harmful pressure on the conduction tissue is reduced. 4,6 Thus, the MFO metal mesh design does not cause the membranous septum to be squeezed, which is a major cause of an AV block.…”

“…A limited number of studies regarding feasibility and early effectiveness of this device have been reported. [4][5][6] However, mid-term results have not been reported. Here, we present our centres' results in order to investigate mid-term efficacy and safety of MFO device in transcatheter perimembraneous ventricular septal defect closure.…”

Safety and efficacy of Amplatzer duct occluder II and konar-MF™ VSD occluder in the closure of perimembranous ventricular septal defects in children weighing less than 10 kg

“…Both devices, with their soft profiles and small delivery sheaths, allow for retrograde or antegrade approaches during implantation ( 21 , 22 ). The ability to be screwed from both sides facilitates the positioning and manipulation of the discs without anatomical constriction on the right side, particularly in pmVSDs with wide and aneurysmal tissue, making the MFO device advantageous compared to ADOII ( 23 ).…”

Pulmonale Hypertonie bei Erwachsenen mit angeborenen Herzfehlern im Lichte der 2022-ESC-PAH-Leitlinien

“…Bei Patienten mit einer relevanten Erkrankung des LV ist ein partieller ASD-Verschluss zu erwägen [10,11] tioneller VSD-Verschluss ist mit selbstzentrierenden Nitinol-Okkludern, Spiralen und konischen Duktus-Okkludern möglich, wenn die Anatomie des Defekts deren Implantation ohne Kompromittierung angrenzender kardialer Strukturen erlaubt [12][13][14][15][16].…”